Application of circulating tumor DNA detection in prediction of curative effect of non-small cell lung cancer / 肿瘤研究与临床

ABSTRACT

Lung cancer is the malignant tumor with the highest mortality in the world, of which non-small cell lung cancer (NSCLC) accounts for about 80%. The orderly combination of surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy is currently the main treatment modality for NSCLC. Liquid biopsy has been increasingly used in clinical practice in recent years due to its advantages of being non-invasive and overcoming tumor heterogeneity, of which circulating tumor DNA (ctDNA) is one of the most commonly used analytical indicators, and ctDNA detection may play a role in the treatment of NSCLC. This article reviews new developments in the use of ctDNA for prognostic assessment, recurrence monitoring and efficacy prediction in NSCLC patients.